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Mariano Barbacid:
Bringing cancer
biology back home
Malen Ruiz de Elvira
After spending half of his life in the
US, where he achieved considerable
recognition as a discoverer of human
oncogenes first and a researcher in
molecular oncology afterwards,
Spanish biologist Mariano Barbacid,
now 50 years old, returned to Spain
two years ago, full of hope and of
plans for a first class research centre
on oncology. He can now keep a
close eye on the old hospital, in
which the new Carlos III National
Centre for Research in Oncology
(CNIO) is being built in north
Madrid, keeping his people in the
meantime working in space lent to
him by the National Centre for
Biotechnology, also in Madrid. The
CNIO building is not due to be
completed until next year but he is
optimistic it will get funded. “Two
years ago, I began from zero, I did
not even have a computer, but I am
not complaining”, he says. “It would
have been utopian to have waited for
the building to be finished (around
June 2001) before returning.”
Barbacid, who is generally
considered by his colleagues as a
very competitive researcher, a good
scientist and a good and austere
manager, was the most prestigious
and well-known Spanish scientist
working outside of Spain. His return
was welcomed by the prime minister,
Jose Maria Aznar, who offered him
the opportunity to lead a new and
ambitious research centre, with
2,300 million pesetas (13.8 million
euros) for the first year (2000) and
1,000 million more (6 million euros)
more for the second year. But even
this short-term commitment is now
in doubt, as the health minister,
Celia Villalobos, would like to make
the pharmaceutical industry pay
most of next year’s bill, while
Barbacid hopes that the government
will keep its promise. The task was
much more challenging to him, he
admits, than if he had been offered a
similar project in the US.
Nevertheless, he does not like to
think that he is unique and
welcomes the creation of similar
institutions — most notably one on
cardiovascular diseases led by
British-Honduran researcher
Salvador Moncada — to create a solid
research basis for the Spanish public
health system. 
Some Spanish scientists think
that the public money that will go to
CNIO will shrink the funds for their
own work in oncology but Barbacid
says the community is so small that
there is no danger of duplicating
work: “We have excellent relations
with other groups, and I wish there
were ten other centres like this in
Spain”. For the time being, CNIO is
unique in Spain, as it will operate as
a private enterprise through a
foundation and will receive money
from the national budget, the
Spanish and European research
programs and also from the
pharmaceutical industry and private
donors. Moreover, the researchers
work under contracts, they will not
be government officials for life as is
predominant in the rest of the
Spanish public research centres and
universities. This in itself is
something revolutionary for Spanish
science and has created resentment
among certain groups. 
The CNIO will tackle both basic
and ‘translational’ research in a
flexible environment. Its first project
will be one of applied science in
molecular pathology to develop
biochips. The new genetic assays
can quickly and automatically
analyse individual genomes for use
in cancer diagnosis within the
national health system. The biochips
will indicate the clinical behaviour of
the tumour and its reaction to drugs.
“It is a priority program which will
take from three to five years to get
established”, says Barbacid. There
will also be a drug discovery program
in oncology similar to the ones in
pharmaceutical companies. “We will
not work with patients, we will do
the preclinical research and the
hospitals will continue the work
from there”. Finally, there will be
basic research on the mechanisms
that are involved in the origin of
tumours and on cancer genetics,
such as the identification of modifier
genes, which influence the
development of tumours.
“I have been very lucky because
I have worked through one of the
most fruitful periods in biomedical
research on cancer”, says Barbacid.
“But after my nearly ten years
experience in Bristol–Myers Squibb
as head of research in oncology, what
I would really like to do is to
translate this golden age of science
into drugs to fight cancer. I think this
is the time for an important effort in
applied research”. One thing the
CNIO will not work on, for the time
being, is gene therapy. “I have
decided to leave it out for the
moment”, he says. 
At the end of its birth process,
around 2005, the CNIO will have
some 20 groups in basic research: but
there is no rush to grow. “Our
scientific council has told us not to
hurry, to let things develop at their
own rhythm”.
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Coming home: Mariano Barbacid is setting
up a world-class cancer research centre in
Madrid after a career developed in the
United States.
